Revivent TC Less Invasive Ventricular Enhancement Therapy CE Mark Extended to 2024

Revivent TC Less Invasive Ventricular Enhancement Therapy CE Mark Extended to 2024

BioVentrix, Inc., developer of the first transcatheter device for left ventricular remodeling after a heart attack, has announced the extension of the system's CE Mark.Recently covered on our pages with news of promising one year study data, Revivent is a less invasive ventricular...

Latest News

Cardiology

Approvals / Clearance

Clinical Studies / Trials